Clinical Trial Finder | Pancreatic Cancer Action Network

Phase II, Prospective, Multinational, Multi-Center, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer (PROTACT)

Summary

The purpose of this phase II study is to assess the response rate of siG12D-LODER with chemotherapy treatment (gemcitabine+nab-paclitaxel) in patients with unresectable, locally advanced pancreatic cancer.

For more information about the study, please visit: http://pancan-protact.com/

General Information

NCT#: NCT01676259
Study ID: SLSG12D-P2
Trial Phase: Phase II

Trial Sponsor: Silenseed Ltd.
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, siG12D-LODER™

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.